Inosine

General characteristics. Structure:

1 tablet contains inosine 0,2 g;
excipients: calcium stearate, potato starch, sugar-powder, mix for a covering.

Pharmacological properties:

Pharmacodynamics. Inosine has anti-hypoxemic, антиаритмическимн properties, anabolic action. He is a predecessor of ATP, directly participates in exchange of glucose and promotes activation of metabolism in the conditions of a hypoxia and in the absence of ATP. Drug activates metabolism of pyruvic acid for ensuring normal process of tissue respiration and
promotes activation of a xanthinedehydrogenase. Inosine positively influences a metabolism in a myocardium, in particular increases power balance of cells, stimulates synthesis of nucleotides, increases activity of a number of enzymes of a tricarbonic acid cycle. Drug normalizes contractility of a myocardium and promotes full relaxation of a myocardium in a diastole due to ability to connect the calcium ions which got into cells in a phase of their excitement activates an angenesis (especially a myocardium and a mucous membrane
digestive channel).

Pharmacokinetics. Drug is well absorbed in the digestive channel. With a current of blood comes to cells where can turn into nucleotides which participate in energy and protein metabolism. Inosine is metabolized in a liver with formation of glucuronic acid and the subsequent its oxidation. Excretes preferential with urine, it is insignificant - with excrements and bile.

Indications to use:

Complex treatment of coronary heart disease (a state after a myocardial infarction, stenocardia), disturbances of a heart rhythm, intoxication drugs of cardiac glycosides, treatment of cardiomyopathies of various genesis, myocardites (against the background of physical overworks), liver diseases (hepatitises, cirrhosis, fatty dystrophy of a liver), an urokoproporfiriya; prevention of a leukopenia at radiation. As the means improving visual functions Inosine is applied at otkrytouglovy glaucoma with normalized (by means of anti-hypertensive drugs) intraocular pressure.

Route of administration and doses:

Inosine is accepted inside, before food. The daily dose for adults and children of advanced age is established individually and makes 0,6 - 2,4 in days. Usually in an initiation of treatment drug is appointed in a daily dose of 0,6 - 0,8 (on 1 tablet 3-4 times a day). If drug is well transferred, a dose gradually (within 2-3 days) raise at first to 1,2 g a day (2 tablets 3 times a day), further - on 2,4 g a day (on 4 tablets 3 times a day). At an urokoproporfiriya Inosine is appointed on 0,8 g a day (on 1 tablet 4 times a day). Duration of a course of treatment - 1 - 3 month.

Features of use:

At a renal failure use of drug is possible only when, according to the doctor, the expected positive effect exceeds possible risk at use. During treatment it is regularly necessary to control the level of uric acid in blood. Drug has no negative effect on ability to drive the car and to work with difficult mechanisms.

Side effects:

Patients with hypersensitivity to drug can have an itch, a dermahemia. In rare instances at treatment there can be an increase in level of urea in blood, at long treatment - an exacerbation of gout. At emergence of side reactions drug should be cancelled.

Interaction with other medicines:

At simultaneous use of Inosine with beta adrenoblockers the effect of Inosine does not decrease. In
combination to cardiac glycosides drug can prevent developing of arrhythmias and strengthen inotropic action.

Contraindications:

The increased individual sensitivity to drug. Gout, hyperuricemia. Restriction to administration of drug is the renal failure.

Overdose:

The individual intolerance of drug in the form of an itch, dermahemias is possible (drug is cancelled and carry out the desensibilizing therapy).

Storage conditions:

To store in the unavailable to children, dry, protected from light place at a temperature from +15 °C to +25 °C. A period of validity - 3 years.

Issue conditions:

According to the recipe

Packaging:

No. 10x5 of tablets in a blister strip packaging and a pack.